Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02272686|
Recruitment Status : Terminated (Slow Accrual)
First Posted : October 23, 2014
Results First Posted : December 5, 2018
Last Update Posted : December 5, 2018
|Condition or disease||Intervention/treatment||Phase|
|Lymphoma||Drug: Ibrutinib||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Targeting Bruton's Tyrosine Kinase (BTK) With Ibrutinib After Autologous Stem Cell Transplantation in "Double-Hit" B-Cell Lymphoma|
|Actual Study Start Date :||June 3, 2016|
|Actual Primary Completion Date :||December 22, 2017|
|Actual Study Completion Date :||December 22, 2017|
Ibrutinib started at a daily dose of 560 mg by mouth daily for up to 3 years.
560 mg by mouth daily.
- Disease Free Survival (DFS) [ Time Frame: Two years ]Participants will be assessed for disease status and survival.
- Overall Survival (OS) [ Time Frame: Three Years ]Participants will be assessed at 3 year time point for survival.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02272686
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Issa F. Khouri, MD, BS||M.D. Anderson Cancer Center|